Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1993;29A(11):1542-6.
doi: 10.1016/0959-8049(93)90291-m.

Randomised Study of Immunotherapy With OK-432 in Uterine Cervical Carcinoma

Affiliations
Clinical Trial

Randomised Study of Immunotherapy With OK-432 in Uterine Cervical Carcinoma

F Kikkawa et al. Eur J Cancer. .

Abstract

OK-432, a streptococcal preparation, was administered to patients with stage Ib and II cervical carcinoma except for adeno- and adenosquamous carcinomas. To evaluate the efficacy of OK-432 precisely, 177 patients were stratified by clinical stage, radiotherapy, and lymph node metastasis after complete radical hysterectomy and pelvic lymphadenectomy. Within each stratum, patients were divided randomly into OK-432 and control groups. 85 patients received OK-432 and 92 patients did not. No significant difference was observed in overall 5-year disease free rates between the OK-432 and the control groups, although the mean diameter of erythema on SU-polysaccharide (SU-PS) skin test was larger in the OK-432 group than in the control group. In stage IIb, a significant difference was observed between the OK-432 and control groups. This difference, however, could be attributed in part to the different incidence of the lymph node metastasis. In stage II without lymph node metastasis, 5-year disease free rate was significantly higher in the OK-432 group.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

Publication types

Feedback